



50 Genentech

A Member of the Roche Group



**Pharmaceutical Industry
Fellowship Program
2027 - 2028**

in conjunction with



**RUTGERS HEALTH
Institute for Pharmaceutical
Industry Fellowships**



Genentech

A Member of the Roche Group



*Doing now
what patients
need next*

DEAR PROSPECTIVE FELLOW

On behalf of the Roche Group and the Ernest Mario School of Pharmacy (EMSOP) at Rutgers University, we thank you for your interest in a Fellowship at Genentech, a member of the Roche Group. A global pioneer in healthcare since 1896, Roche is a world leader in biotechnology and in vitro diagnostics, creating and delivering innovative medicines and diagnostic tests for patients worldwide. We are passionate and rigorous about our science. With a history of more than 35 years in the Fellowship, Roche has also played a major role in fostering the professional growth of pharmacists in pharmaceutical research, development, and commercialization. We offer motivated PharmD graduates, who share our purpose to improve the lives of patients, exciting opportunities to develop their skills and pursue their interests at Genentech's US Headquarters for Roche Pharmaceutical Operations in South San Francisco, California, where the biotechnology industry began and continues to thrive.

We aim to cultivate one of the best educational environments for PharmD graduates through our commitment to quality and excellence. Fellows have the opportunity to develop or enhance their knowledge and skills while experiencing a corporate culture that encourages diversity of thought, style, skill, and perspective as well as a dynamic environment of international colleagues. While the Fellowship is structured, it is still flexible enough to allow participants to engage in a wide array of unique opportunities and obtain a solid experience in the healthcare industry. We look forward to meeting you and discussing how this program can serve as your pathway to an exciting career in the pharmaceutical industry helping to improve patients' lives.



Patrick Schleck,
PharmD, MBA, RUCIF
*Vice President,
Pharma Partnering Oncology
Genentech RPIF Program Director*

TABLE OF CONTENTS



4

About Roche
& Genentech



6

Genentech at
a Glance



8

Fellowship
Components



10

Overview of
Fellowship
Positions



11

Fellowship
Position
Descriptions



16

Rutgers
Program

ABOUT ROCHE & GENENTECH




MEET THE LEADERSHIP TEAM



PATRICK SCHLECK, PharmD, MBA, RUCIF
Vice President, Pharma Partnering Oncology
Genentech RPIF Program Director



MICHAEL STAMATIS, PharmD, RUCIF
Senior Program Director, Product
Development Regulatory



JAN BHAGWAKAR, PharmD, RUCIF
National Medical Science Liaison Director,
CVRM



TONY LIN, PharmD, RUCIF
Vice President and Therapeutic Area Head,
US Medical Oncology-Hematology

WHO WE ARE



We have always worked to drive scientific discovery and redefine what is possible to improve patients' lives. We are working on understanding how diseases differ down to the molecular level to develop new tests and medicines that prevent, diagnose, and treat diseases that matter and bring them to the patients who need them. With our combined strengths in diagnostics and pharmaceuticals, our personalized healthcare strategy aims to fit the right treatment to the right patient.

As the world's largest biotech company, we develop breakthrough medicines, improving the standard-of-care across oncology, immunology, infectious diseases, ophthalmology and neuroscience. This track record allows us to build lasting and meaningful partnerships across the world with research academia and public healthcare institutions. The founding families continue to hold the majority stake in the company. This stability allows for a tradition of sustainable thinking, so we can learn from setbacks and focus on lasting value for patients and society. We remain dedicated to the highest standards of quality, safety, and integrity. Our legacy is based on respect for the individual, the communities and the world we live in.

OUR PURPOSE



We believe it is urgent to deliver medical solutions right now – even as we develop innovations for the future. We are passionate about transforming patients' lives. We are courageous in both decision and action. And we believe that good business means a better world. That is why we come to work each day.

We commit ourselves to scientific rigor, unassailable ethics, and access to medical innovations for all. We work to foster belonging for our people, and advance inclusive research and health equity for all patients. We do this today to build a better tomorrow. We are proud of who we are, what we do, and how we do it. We are many, working as one across functions, across companies, and across the world.

Innovation: It's in our DNA



ABOUT ROCHE & GENENTECH



OUR HISTORY

Founded in 1976, Genentech is a leading biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.

In 2009, Genentech became a member of the Roche Group—now one of the largest biotechnology companies in the world. Genentech's South San Francisco campus serves as the headquarters for Roche pharmaceutical operations in the United States.

Today, as a member of the Roche Group, we are the global leader in personalized healthcare, leveraging our combined strengths across pharmaceuticals, diagnostics and data insights to fundamentally change the way diseases are treated.



46	MEDICINES IN THE WORLD HEALTH ORGANIZATION MODEL LIST FOR ESSENTIAL MEDICINES
43	FDA BREAKTHROUGH THERAPY DESIGNATIONS
40+	FDA-APPROVED MEDICINES FOR SERIOUS & LIFE-THREATENING DISEASES
66	INVESTIGATIONAL DRUGS IN DEVELOPMENT

\$15 B
IN RESEARCH & DEVELOPMENT


~250
CLINICAL TRIALS IN THE U.S.

~600
CLINICAL TRIALS WORLDWIDE

5 AREAS OF FOCUS

ONCOLOGY - HEMATOLOGY, NEUROLOGY,
OPHTHALMOLOGY, IMMUNOLOGY,
CARDIOVASCULAR, RENAL & METABOLISM (CVRM)

GENENTECH AT A GLANCE



*In 1985, Genentech received FDA approval to market its first medicine, Protopin — the first recombinant pharmaceutical medicine to be manufactured and marketed by a biotechnology company. Manufacturing was discontinued in 2002. In 1998 we licensed U.S. marketing and development rights to interferon gamma, including Actimmune, to Connetica Corporation. Thereafter, Connetica sublicensed, then later assigned, all of its rights to InterMune Pharmaceuticals, Inc. Protopin manufacturing was discontinued at the end of 2002. Nutropin Depot commercialization was discontinued in June 2004. On April 8, 2009, Genentech announced a phased voluntary withdrawal of the psoriasis drug Raptiva from the U.S. market. On December 31, 2024, Genentech will discontinue all Nutropin AQ[®] (isomaltropin) Nutropin[®] formulations in the United States. The decision to discontinue Nutropin was made after a thorough assessment by Genentech and is based on a combination of business considerations and the availability of alternative growth hormone options for patients. This action is unrelated to the current supply shortage or any product quality, safety, or efficacy issues. The U.S. Food and Drug Administration (FDA) has been notified. Ensuring the well-being of patients is Genentech's top priority, and we are committed to supporting patients and healthcare providers during this transition.

CULTIVATING A GREAT WORKPLACE

12,100

U.S. employees united by a passion for science and a culture of belonging, ensuring the world's most talented people can do their best work for the patients we serve.

Charitable Contributions Advance Science and Support Patients and Local Communities

\$230M

in education, health access, and community wellbeing to remove the barriers between scientific breakthroughs and the people who need them since 2017


10+ years

operated Futurelab, a STEM education program that supports **8,000** K-12 students annually in the South San Francisco Unified School District.

≥\$4.8M

Invested into small businesses across several U.S. sites for 31 years through **Genentech Goes to Town**

ROCHE GROUP



FELLOWSHIP COMPONENTS

At Genentech, fellows are valuable assets within their chosen functional area. Rooted in our commitment to pursuing groundbreaking science and addressing unmet needs, this robust program builds the best leaders in the pharmaceutical industry. It has established a lasting tradition of furthering the development of fellows, allowing them to fine tune skills, fully integrate into a corporate setting, network, and make lasting contributions for patients.



MENTORSHIP PROGRAM

The mentorship program pairs fellows with experienced mentors currently on their team either within Genentech or Roche. This provides the fellow with additional support in their day-to-day activities outside of their co-fellows & preceptors.

The mentorship program aims to give fellows continued career guidance and professional development through the collaborative efforts of Genentech and Roche.



NETWORKING OPPORTUNITIES

- **Pharmacists Network**
Network with other PharmDs at Genentech
- **Genentech Rotational Network**
Network with other early talents completing rotational programs at Genentech
- **Training & Development Partnership**
Provides training across functional roles and therapeutic areas for commercial colleagues and provides soft skills & behavioral trainings for all Genentech employees





ROTATION OPPORTUNITY

At Genentech, we prioritize the development of each fellow. Our fellowships are structured to maximize exposure to various roles within industry, specifically within the fellow's chosen functional area. Certain fellowships offer a rotational opportunity during the fellow's second year in order to gain hands-on experience in an additional functional area of interest.



FELLOWSHIP ALUMNI NETWORK

- Roche was one of the first companies to partner with RPIF
- There are 50+ RPIF EMSOP Alumni currently employed at Roche/Genentech
- Many preceptors & Fellowship Leadership Team members are RPIF EMSOP alumni & are actively engaged



PROFESSIONAL CURRICULUM

- Professional Development series at the Ernest Mario School of Pharmacy (EMSOP)
- Optional Teaching and Learning Certificate Program at EMSOP
- Genentech skill development courses customized to Fellow interest each year



SOCIAL

LinkedIn, Facebook, Instagram: [@RutgersFellow](#)
Rutgers Website: pharmafellows.rutgers.edu

OVERVIEW OF FELLOWSHIP POSITIONS

Recruiting for 2027 – 2029
(all positions are two years in length)

**2
Fellows**

[Global Clinical Operations](#)

**1
Fellow**

[Product Development](#)
[Clinical Safety](#)

**1
Fellow**

[Clinical Science](#)
[Late Stage Development](#)

**3
Fellows**

[USM /](#)
[Medical Science Liaisons](#)

**1
Fellow**

[Pharma Partnering](#)



GLOBAL CLINICAL OPERATIONS

OVERVIEW

At Roche/Genentech, the mission of Product Development Global Clinical Operations (PDG) is to deliver patient-centric clinical trials to patients around the world. Our aim is to prioritize speed, cost-effectiveness, efficiency and quality in our clinical studies to ultimately deliver our portfolio to patients. We do so through fostering collaborative relationships, ensuring inclusive research, and emphasizing study risk assessment. Our shared purpose is to innovate clinical trial delivery to transform Roche's patient, caregiver, and site experience to bring better trials to more patients.

Global Clinical Operations fellows will have the opportunity to work cross-functionally to contribute to the execution and delivery of Roche/Genentech's portfolio of innovative medicines. Fellows will play integral roles on study management teams and will be involved in critical decision making, development and management of study plans and timelines, and collaboration with external stakeholders.

ACTIVITIES

Fellow responsibilities may include:

- Coordinate and deliver the study management aspects of a group of studies within an asset's portfolio
- Provide input into the development of essential study level documents (eg Study Protocol, TMP, Pharmacy Manual).
- Develop a study's recruitment expectations in partnership with relevant stakeholders
- Develop and/or maintain relevant study plans/ relevant training materials
- Drive innovation in clinical operations by thinking of and contributing to the implementation of new approaches
- Build and role model effective study partnership behaviors and mindsets with Contract Research Organizations (CROs)
- Develop and oversee key performance indicators (KPIs) to communicate risks to timelines and/or quality to your Global Studies Leader
- Maintain inspection readiness of the relevant components in scope of responsibility
- Lead 3rd party vendor selection, oversight, and close out to ensure delivery to contract
- Produce, arrange translation, and distribute patient and site facing support materials
- Manage supply and shipment of investigational medicinal products
- Obtain and distribute clinical trial insurance

PRECEPTORS

11



Leah Peters

Global Operations Asset Leader
Product Development, Clinical Operations



Patrycja Bulley

Global Operations Asset Leader
Product Development, Clinical Operations

Recruiting Positions
Global Clinical Operations

Number
2

2025-2027 FELLOWS



Justin Lenhard, PharmD, BCIDP
University at Buffalo



Swathi Kompella, PharmD
Rutgers University, EMSOP

PRODUCT DEVELOPMENT CLINICAL SAFETY

OVERVIEW

The Portfolio Clinical Safety (PCS) group within Product Development Safety delivers knowledge on the safety profiles of our medicines and defines how we manage risks to patients receiving our medicines. Our Pharm.D. fellow will work collaboratively with experienced PCS Safety Scientists and cross-functional colleagues to learn to monitor and manage the safety of our molecules. This includes exposure to molecules in early development, late stage development and marketed medicines. The activities performed by PCS bring strategic, proactive, and scientific value to our pharmacovigilance and risk management strategies. This work ensures that Roche products maintain a positive benefit-risk balance for our patients.

ACTIVITIES

Fellow responsibilities include:

- Learning and understanding global requirements for the reporting and surveillance of adverse events
- Evaluation and analysis of adverse events received from clinical trials and from postmarketing reports
- Maintenance and update of safety related information in product labels, investigator brochures, and informed consent forms
- Contributing to safety strategy in study design and study management
- Preparation of aggregate safety reports for health authorities
- Risk management plan development and maintenance
- Cross-functional interactions supporting projects with other departments within Product Development and the broader Roche organization
- Gaining knowledge of end to end drug development, including both early and late stage clinical development
- Special projects

PRECEPTORS

12



Sam McCallum, PharmD
Senior Safety Director,
Late Stage and Marketed Medicine Safety



Sam Lim, PharmD
Safety Director,
Portfolio Clinical Safety

Recruiting Positions
Clinical Safety

Number
1

2026-2028 FELLOW



Derek Bassett, PharmD
UNC Chapel Hill

CLINICAL SCIENCE LATE STAGE DEVELOPMENT

OVERVIEW

The development of effective and safe medications for patients is our primary focus at Genentech. The mission of Product Development Clinical Science (PDC) is to develop and execute innovative and robust development programs to deliver well-characterized and differentiated medicines to patients with unmet medical need. PDC includes 2 therapeutic areas: Oncology/Hematology (PDOH) and Innovation, Immunology, Infectious Diseases, as well as Ophthalmology, Neuroscience, Nephrology (PD ION).

The Fellows accepted into our program will have a contributing role in clinical trial design and execution by assisting in writing protocols, informed consents, medical data review, scientific publications and presentations, as well as providing ongoing scientific guidance throughout study conduct. The Fellows may also be involved in the analysis of molecule-wide safety signals, analysis of study-related data, and contribute to authorship of regulatory documents.

ACTIVITIES

PDC specializes in late stage clinical development, conducting primarily Phase II/III clinical trials with an aim to further characterize the clinical efficacy and safety profile of a molecule before the registration/approval process. During the fellowship, the Fellow will receive professional experiences in the following capacities:

- Develop a deep understanding of the molecules in the late-stage pipeline
- Ascertain the risk/benefit profile of tested molecules and understand the criteria for moving further in development
- Author key scientific documentation for clinical studies
- Assist in ongoing clinical development plans by working closely with Clinical Scientists and Medical Directors on strategic initiatives
- Enhance scientific communication skills through presentations, medical congresses and professional meetings

PRECEPTORS

13



Sarah Troutman, PharmD
Senior Clinical Scientist,
Product Development Oncology/Hematology



Iris To, PharmD
Principal Clinical Scientist,
Product Development Oncology/Hematology

Recruiting Positions
Oncology/Hematology (PDOH)

Number
1

2026-2028 FELLOW



Vidisha Amin, PharmD
Albany College of Pharmacy and Health
Sciences

US MEDICAL / MEDICAL SCIENCE LIAISONS

OVERVIEW

A network of clinical and scientific collaborators is responsible for developing and executing medical strategy for both marketed and pipeline molecules for the US affiliate. The network supports Medical Science Liaison (MSL) activities by serving as subject matter experts and ensuring strategic alignment across Medical Affairs.

The US Medical / MSL Fellowship is a two-year program based in South San Francisco, designed to expose the Fellow to a broad range of corporate and field-based US Medical Affairs activities within their assigned Medical Unit. The focus of the second year is determined by the mutual interests of the Fellow and the company.

ACTIVITIES

Medical Affairs Component:

The Fellowship will provide the Fellow with a thorough knowledge of US Medical core functions and develop foundational scientific and professional skill sets required for a successful career. The Fellow will have the opportunity to participate in or lead:

- Tactic execution with the Medical Directors and Medical Science Directors who support medical strategy
- Pre- and peri-approval preparations for new molecular entities
- Clinical insights with colleagues across various cross-functional departments
- Development of training and tools for the Field Medical Team
- Collaborative studies and activities across NCI, Academic Alliances, and Community Networks

MSL Component:

Alongside the Medical Affairs experience, the Fellow will have the opportunity to participate in or lead:

- MSL strategy planning and execution with MSL leadership
- In-field scientific exchange with providers and key opinion leaders
- Execution of advisory boards and congress tactics

PRECEPTORS

14



Tony Lin
Vice President & Therapeutic Area Head
Oncology Hematology



Allan Ding
Principal Medical Science Director
Ophthalmology



Daniel Lee
Senior Medical Science Liaison
Ophthalmology

Recruiting Positions	Number
USM/MSL Ophthalmology	1
USM/MSL Oncology	1
USM/MSL Immunology	1

2025-2027 FELLOWS



Harman Kaur, PharmD
Keck Graduate Institute

2026-2028 FELLOWS



Katy Xia, PharmD
The Ohio State University



Jarret Morgan, PharmD
Southern Illinois University

Genentech
A Member of the Roche Group

PHARMA PARTNERING

Recruiting

OVERVIEW

Partnering strengthens Roche's internal research, development, and commercial portfolio by building alliances with world-class leaders in the pharmaceutical and biotechnology industries. By mobilizing other functions at Roche and Genentech, Partnering maximizes the potential of these assets through creative deal terms and fostering a collaborative relationship with the external partner. In Pharma Partnering, the Fellow has the opportunity to work in the Business Development and Alliance Management Groups.

ACTIVITIES

The Business Development role encompasses "Want," "Find," and "Get," including:

WANT and FIND

- Scouting: Identify new partnering opportunities using internal and external sources. Prepare in-depth competitive landscape analyses, reviews of disease biology and unmet need in areas of interest. Support preparation and analysis of scientific, partnering, and investor conferences.
- Triage: Support initial screening and review of data packages from Biotech and Pharma partners to determine Roche interest based on: mechanism of action, link to human disease biology, unmet need, strategic fit, and commercial opportunity.

GET

- Due Diligence: Work in close collaboration with BD Project Leader (BDPL) to assist in data review, DD team debriefs, and preparation of proposals to senior management.
- Deal Team: For deal negotiations, work with BDPL to prepare term sheets, governance, and contracting.

The Global Alliance and Asset Management role encompasses "Manage", including:

- Liaising with the alliance counterpart and senior leadership of partner companies.
- Effective leadership of collaborations between external companies and Genentech/Roche.
- Integral part of the Business Development deal team during deal negotiations and contracting.
- Lead and negotiate deals arising from existing alliances.
- Establish and lead joint governance committee meetings to ensure appropriate decision making on partnered programs.
- Participate in out-partnering or divestment opportunities.

PRECEPTORS

15



Patrick Schleck, PharmD, MBA
Vice President,
Pharma Partnering Oncology

2025-2027 FELLOW



Zoe Nicole Amaris, PharmD
University of Washington

~60% of R&D pipeline involves a partnership

250+

partnerships managed and 51 new agreements signed in 2025 by Pharma Partnering



Rutgers Pharmaceutical Industry Fellowship (RPIF) Program

Ernest Mario School of Pharmacy (EMSOP)

Rutgers, The State University of New Jersey

The RPIF Program has thrived under the leadership of the founder, Dr. Joseph A. Barone, Dean and Distinguished Professor of EMSOP, Dr. Carolyn Seyss, the Executive Director for the Institute for Pharmaceutical Industry Fellowships, and is supported by a team of RPIF alumni experienced in the pharmaceutical industry.



**Joseph A. Barone,
PharmD, FCCP**
*Dean and Distinguished
Professor*



**Carolyn Seyss,
PharmD, RUCIF**
*Fellowship
Executive Director*



**Joseph Fulginiti,
PharmD, MBA, RUCIF**
RPIF Associate



**Erica Dankiewicz,
PharmD, RUCIF**
RPIF Consultant



**Patrick Park,
PharmD, MBA, RUCIF**
RPIF Consultant

Program History

1984

EMSOP and 2 pharmaceutical companies began a first-of-its-kind collaborative pilot program to evaluate the potential contributions of clinically- trained pharmacists within a pharmaceutical industry practice setting. Following the successful pilot, the RPIF Program grew significantly and expanded to now include 26 companies within the pharmaceutical and biopharmaceutical industry with almost 300 Fellows.

2002

Dr. Ernest Mario generously provided an endowment to establish RPIF as an Institute to enhance and promote the role of pharmacists in industry through the RPIF Program. The Institute staff members:

- Create the Fellowship structure, providing strategic leadership and administrative support
- Promote quality, communication, scholarly activity, and professional development
- Arrange specialized training opportunities within the pharmaceutical and biopharmaceutical industry

2018

RPIF expanded to offer interdisciplinary Fellows' training by adding physician Fellowship opportunities to our well-established program.

2023

The RPIF Certificate is recognized with special credentials so our alumni can now proudly identify themselves as **RUCIF (Rutgers University Certified Industry Fellow)**.

Well over 1,900 Post-Doctoral Fellows have completed the RPIF Program, most of whom are experiencing influential and rewarding careers in the pharmaceutical and biopharmaceutical industry throughout the US and abroad. The RPIF Program has Preceptors and Mentors from industry who share their knowledge and experiences with the Fellows through an intense but closely-guided training program. Assignments and projects are challenging, meaningful, and designed to enhance understanding of the pharmaceutical and biopharmaceutical industry and the Fellow's functional area(s). Our goal is to provide the environment for Fellows to build the foundations to fuel their careers as future leaders in the industry.

Professional Development Series

All Fellows gather once monthly as a group to participate in the Professional Development Day (PDD) series, an important component of their training that complements the hands-on experience provided at the sponsor companies. The PDDs are steered by a committee of Fellows and are designed to enhance the Fellows' leadership skills such as emotional intelligence, communication, critical decision making, and presentation skills. Fellows develop skill sets under the guidance of external trainers and accomplished RPIF alumni. PDDs also provide general knowledge about various aspects of drug development/ commercialization and issues facing the pharmaceutical and biopharmaceutical industry, and promote connectivity and a sense of community among Fellows and alumni from different companies and disciplines.

The Fellows can learn from each other through individual and group presentations on topics and issues related to the pharmaceutical and biopharmaceutical industry. In addition, outside experts provide training and professional development in a variety of areas (e.g., tools for corporate success, professional writing, presentations, meeting facilitation, negotiating, influencing, networking, conflict resolution, giving and receiving feedback, and business etiquette). Other PDD guest speakers include senior industry executives, including our successful RPIF Program alumni, who share their career paths, insights, and experiences. Importantly, PDDs provide an excellent opportunity for Fellows to interact with each other and develop lasting personal friendships and a strong professional network of Fellows, faculty, alumni, and other industry executives.

Key Program Features

RPIF FOSTERS the growth and development of future pharmaceutical and biopharmaceutical industry professionals and leaders through:

F	Family of Leading Companies Partners include several top global pharmaceutical/biopharmaceutical companies and offer large to small company environments.
O	Outstanding Alumni Track Record Well over 1,900 alumni hold prominent positions at many leading companies, including VP and C-suite levels.
S	Strong Network Fellows develop valuable, lasting connections with each other, alumni, Preceptors, and Rutgers EMSOP faculty.
T	Trusted and Proven Since 1984 The Rutgers Fellowship Program is nationally recognized, trusted, and proven as the key pathway to industry, developing foundations for future leaders.
E	Enhanced Career Development Breadth of experiences informs career path choices, increasingly challenging assignments build depth of experience, and visibility creates opportunities - enhancing the potential for accelerated career paths.
R	Rigorous Academic Component Rutgers affiliation provides academic and professional development opportunities.

Because of its relationship with and close proximity to most of the nation's leading pharmaceutical and biopharmaceutical companies, EMSOP and the RPIF Program are uniquely capable of providing Fellows with advanced training in the pharmaceutical and biopharmaceutical industry.

Rutgers, The State University of New Jersey is one of the major state university systems in the United States. EMSOP is part of Rutgers Health and is the only state school of pharmacy in New Jersey. EMSOP is located on the University's main science and technology campus in Piscataway, New Jersey.

While RPIF offers all the benefits of a large program with an extensive network of distinguished professionals, Fellows receive the individual attention of a small program where they are known and supported as individuals.

Application Process and Eligibility Requirements

Pharmacy Fellows for the RPIF Program are selected on a nationally competitive basis. Candidates must have completed a Doctor of Pharmacy from an ACPE-accredited institution before July 1 of the fellowship term.

HOW TO APPLY:

The RPIF Program is highly competitive. **Candidates will be selected for interviews on a rolling basis, so we strongly encourage you to submit your application as soon as possible.**

Interested candidates may submit their application with short-answer questions and supporting materials (letter of intent, curriculum vitae, and 3 letters of recommendation) as soon as **Wednesday, October 14, 2026** by visiting our website at: <https://pharmafellows.rutgers.edu/how-to-apply/>

All application materials must be submitted electronically to the RPIF website per instructions on the site.

REQUIRED ITEMS:

SUBMIT BY:

Application with short-answer questions	Tuesday, October 20th
Letter of Intent (LOI)	Tuesday, October 20th
Curriculum Vitae (CV)	Tuesday, October 20th
Letters of Recommendation (LORs)	Tuesday, December 1st

ADDRESS LOI AND LORs TO:

Joseph A. Barone, PharmD, FCCP
Dean and Distinguished Professor
Ernest Mario School of Pharmacy
Rutgers, The State University of New Jersey
160 Frelinghuysen Road
Piscataway, NJ 08854-8020





"My experience as an RPIF Fellow has been one of the most meaningful and transformative parts of my professional journey, providing countless opportunities for growth while reinforcing the importance of giving back to the Ernest Mario School of Pharmacy community. I am grateful to draw upon my nontraditional experiences prior to pharmacy school to mentor, support, and advocate for our RPIF Fellows, encouraging them to embrace their own unique backgrounds as strengths in their professional careers. Investing in their professional and personal development is especially rewarding because today's Fellows will become tomorrow's leaders, advancing innovations that improve the lives of patients and strengthen the communities we serve."

John (Eun Sik) Cho, PharmD
Global GMP QA Strategy



"It is hard to put into words how much this fellowship has meant to me in just my first year. RPIF has challenged me to grow, think differently, and embrace opportunities I never imagined having this early in my career. Knowing that my work has the potential to impact patient care on a global scale has been incredibly rewarding, and I am excited to see how RPIF continues to shape my career and growth as a leader. I encourage future fellows to take advantage of everything the program has to offer because the experiences you gain and the relationships you build will shape your future."

Hillary Anne Reeves, PharmD
Late-Stage Clinical Development



"I am incredibly grateful for the personal and professional growth I have experienced as a Rutgers Fellow. Through RPIF and my partner company, I have been able to learn from inspiring mentors, collaborate with talented peers, and pursue opportunities that have accelerated my development. Being surrounded by such a supportive fellowship community has made this experience especially meaningful and has helped me feel prepared and excited for the future!"

Brynn Gilbert, PharmD
Medical Communications

AIFA
Alliance of Industry Fellowship Associates

Aligned First Offer Date
December 11, 2026

The choice of a Post-Doctoral Industry Fellowship is an important decision. AIFA exists to promote a consensus first offer date for all Fellowship positions. We believe this is a positive reflection of the cultures our Programs offer, and that culture is a critical consideration in choice of Fellowship.

We hope that other academic and non-academic Fellowship Programs will NOT pressure candidates to accept offers prior to this AIFA-aligned offer date. Candidates should feel free to request an extension for any earlier offer to allow them to consider their options.